As the country prepares to vaccinate Children, Pfizer and BioNTech said on Thursday that they aim to deliver 50 million extra doses of their COVID-19 vaccine to the US government by the end of April.

The decision comes after a panel of independent experts to the US Food and Drug Administration agreed on Tuesday to recommend the vaccine's approval for children aged 5 to 11. The vaccine's approval by the government for this age range is still pending.

The businesses said they aim to begin selling the vaccine immediately, in 10 microgram pediatric doses, if the vaccine is permitted and recommended by the US Centers for Disease Control and Prevention's (CDC) advisory group.

FDA says benefits outweigh risks for Pfizer/BioNTech COVID-19 vaccine in  children | Reuters

So far, the US government has obtained 600 million vaccine doses for domestic use and another 1 billion doses for donation to low- and lower-middle-income nations.

Initial clinical trial data on the vaccine's usage in children aged 2 to less than 5 years, and 6 months to less than 2 years, is due in the fourth quarter of this year or the first quarter of 2022, according to the drugmakers.